LEADER 01322nam  2200361Ia 450 
001 9910699125803321
005 20230902162116.0
035   $a(CKB)5470000002400640
035   $a(OCoLC)464691837
035   $a(EXLCZ)995470000002400640
100   $a20091110d2006      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for FDA staff and industry$b[electronic resource] $emarketed unapproved drugs, compliance policy guide
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2006]
215   $a1 online resource (i, 12 pages)
300   $a"Sec. 440.100 marketed new drugs without approved NDAs or ANDAs."
300   $a"Compliance."
300   $a"June 2006."
517   $aGuidance for FDA staff and industry 
606   $aDrugs$xMarketing$xGovernment policy$zUnited States
606   $aDrug approval$xGovernment policy$zUnited States
615  0$aDrugs$xMarketing$xGovernment policy
615  0$aDrug approval$xGovernment policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699125803321
996   $aGuidance for FDA staff and industry$93548131
997   $aUNINA